Vasogen Inc. INVESTOR CONTACT
2155 Dunwin Drive Glenn Neumann
Mississauga, ON, Canada L5L 4M1 Investor Relations
tel: (905) 569-2265 fax: (905) 569-9231 (905) 569-9065
www.vasogen.com [email protected]
--------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
Vasogen's J.P. Morgan H&Q Presentation to be Web Cast
Toronto, Ontario (January 10, 2001) -- Vasogen Inc. (TSE:VAS; AMEX:MEW)
announces that the Company's presentation at the 19th Annual J.P. Morgan H&Q
Healthcare Conference in San Francisco, California will be available to
shareholders and other interested parties via web cast. The presentation, to be
delivered today at 3:30 p.m. PST by David Elsley, Vasogen's President and Chief
Executive Officer, will be web cast live and available for replay at
http://www.chasehq.com/events/index.html .
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory diseases.
These therapies are designed to target fundamental disease-causing events,
providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
